Dalsan You1, Myoung Jin Jang2, Bo Hyun Kim1, Ki Ryung Choi3, Chunwoo Lee4, Geehyun Song5, Ha Chul Shin3, In Gab Jeong1, Nayoung Suh2, Yong Man Kim3, Tai Young Ahn1, Choung-Soo Kim6. 1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 3. Pharmicell Co. Ltd., Seongnam, Gyeonggi, Republic of Korea. 4. Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Gyeongsangnam, Republic of Korea. 5. Department of Urology, Kangwon National University Hospital, Chuncheon, Kangwon, Republic of Korea. 6. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: cskim@amc.seoul.kr.
Abstract
BACKGROUND AIMS: Although clinical studies using stem cells to treat erectile dysfunction have been performed or are ongoing, there is little consensus on the optimal protocol. We aimed to develop a protocol optimizing human bone marrow-derived mesenchymal stromal cell (hBMSC) therapy in a rat model of cavernous nerve injury. METHODS: We performed, in order, a dose-finding study, a toxicokinetic study of hBMSCs, and a study to determine the timing and number of cell injections. RESULTS: From the dose-finding study, 1 × 10(6) cells were selected as the dose per hBMSC injection. From the toxicokinetic study, 14 days was selected as the interval between repeat treatments. In the final study, the ratio of maximal intracavernous pressure to mean arterial pressure was significantly lower in the control group than in the sham group (23.4% vs. 55.1%, P <0.001). An immediate single injection of hBMSCs significantly improved erectile function compared with the control group (39.8%, P = 0.035), whereas a delayed single injection showed improvement with a marginal trend (38.1%, P = 0.079). All histomorphometric changes were significantly more improved in the immediate or delayed single injection groups than in the control group. Repeat treatments did not provide any benefit for the recovery of erectile function and histomorphometric changes. CONCLUSIONS: Intracavernous injection of 1 × 10(6) hBMSCs results in a recovery of penile erection and histomorphometric changes in a rat model of cavernous nerve injury, even when treatment was delayed until 4 weeks after cavernous nerve injury.
BACKGROUND AIMS: Although clinical studies using stem cells to treat erectile dysfunction have been performed or are ongoing, there is little consensus on the optimal protocol. We aimed to develop a protocol optimizing human bone marrow-derived mesenchymal stromal cell (hBMSC) therapy in a rat model of cavernous nerve injury. METHODS: We performed, in order, a dose-finding study, a toxicokinetic study of hBMSCs, and a study to determine the timing and number of cell injections. RESULTS: From the dose-finding study, 1 × 10(6) cells were selected as the dose per hBMSC injection. From the toxicokinetic study, 14 days was selected as the interval between repeat treatments. In the final study, the ratio of maximal intracavernous pressure to mean arterial pressure was significantly lower in the control group than in the sham group (23.4% vs. 55.1%, P <0.001). An immediate single injection of hBMSCs significantly improved erectile function compared with the control group (39.8%, P = 0.035), whereas a delayed single injection showed improvement with a marginal trend (38.1%, P = 0.079). All histomorphometric changes were significantly more improved in the immediate or delayed single injection groups than in the control group. Repeat treatments did not provide any benefit for the recovery of erectile function and histomorphometric changes. CONCLUSIONS: Intracavernous injection of 1 × 10(6) hBMSCs results in a recovery of penile erection and histomorphometric changes in a rat model of cavernous nerve injury, even when treatment was delayed until 4 weeks after cavernous nerve injury.
Authors: Seul Gi Kim; Dalsan You; Kyung Kim; Joomin Aum; Yu Seon Kim; Myoung Jin Jang; Kyung Hyun Moon; Hyun-Wook Kang Journal: World J Mens Health Date: 2021-12-28 Impact factor: 6.494
Authors: Jong Keun Kim; Myoung Jin Jang; Bo Hyun Kim; Ki Ryung Choi; Geehyun Song; Ha Chul Shin; Nayoung Suh; Yong Man Kim; Dalsan You; Tai Young Ahn; Choung-Soo Kim Journal: Investig Clin Urol Date: 2019-12-17